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ABSTRACT 
 
Recently, we reported elevated proportions of circulating follicular T helper cells and higher 
levels of interleukin (IL)-21 in primary Sjögren’s syndrome (pSS). Interaction of invariant 
natural killer T (iNKT) cells with B cells and granzyme B (GrB) production may be also 
important in pSS. 
Thirty-two pSS patients and 24 healthy controls were enrolled in our study. We investigated 
the expression of intracellular GrB and IL-21 receptor (IL-21R) of CD19
+
CD5
+ 
and 
CD19
+
CD5
- 
B cells; furthermore, we determined the IL-21 expression of iNKT cells, as well. 
We also assessed the proportion of transitional (CD19
+
CD24
high
CD38
high
), mature 
(CD19
+
CD24
+
CD38
+
) and primarily memory (CD19
+
CD24
+
CD38
-
) B cells. 
CD5
+
 but not CD5
-
 B cells showed elevated GrB and IL-21R expression in pSS; additionally 
IL-21 expression of iNKT cells was also elevated. The ratios of transitional and mature B 
cells were elevated in pSS, while primarily memory B cell percentages were decreased, which 
correlated with GrB and IL-21R expression of CD19
+
 B cells.   
Our results suggest that enhanced IL-21R expression of CD19
+
CD5
+
 B cells and production 
of IL-21 by iNKT cells may play an important role in the pathogenesis of pSS by regulating 
C19
+
CD5
+
 B cell functions and increasing GrB production, presumably leading to a counter-
regulatory effect in the disease. 
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Introduction 
 
Primary Sjögren’s syndrome (pSS) is a common systemic autoimmune disease characterized 
by inflammation and consequential destruction of exocrine glands. In the last decades, large 
amount of studies confirmed that B cell activation plays a crucial role in the pathogenesis of 
pSS through antigen presentation, autoantibody production and secretion of several pro-
inflammatory factors. The pathological hallmark of pSS is extensive lymphocytic infiltration 
in salivary glands. The extension and structural arrangement of the infiltrations varies 
between wide limits, even ectopic germinal centres may develop. These structures are 
characterized by in situ autoantibody production and high expression of homing and retentive 
chemokines and adhesion molecules. It was reported that the number of ectopic GCs in 
salivary glands correlates with the severity of inflammation and anti-SSA/SSB autoantibody-
production [1,2]. Additionally, formation of ectopic GCs in glandular tissues carries a higher 
risk of developing B cell lymphoma in pSS [3]. 
The proliferation and differentiation of B cells in GCs highly depend on their collaboration 
with follicular helper T (TFH) cells, which are generated from peripheral naive CD4
+
 T cells in 
the T cell zone of lymphoid organs. The appropriate interaction of activated B cells and TFH 
cells is crucial for the generation of extrafollicular short-lived low-affinity plasma cells, high-
affinity memory B cells and long-lived plasma cells [4]. Recent investigations shed light on 
altered TFH profiles in various autoimmune conditions, suggesting the important role of TFH 
cells and IL-21 cytokine secretion in autoreactive B cell activation and autoantibody 
production [4]. In labial salivary gland biopsies of pSS patients, TFH cell markers (CD84, PD-
1, and Bcl-6) were detected in the lymphocytic infiltrations, especially, in more organized 
lymphoid structures [5]. In peripheral blood, elevated CD4
+
CXCR5
+
ICOS
+
PD-1
+
 TFH-like 
cell percentages were reported in pSS, which showed strong association with anti-SSA and/or 
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anti-SSB autoantibody positivity. Moreover, patients with higher TFH cell proportions had 
elevated IL-21 serum levels [6].  
As part of immune responses, IL-21 is produced by activated CD4
+
 T cells and natural killer 
(NK) T cells. IL-21-activated B cells produce IL-6, which further activates B cells in an 
autocrine manner and contributes to TFH cell differentiation and autoantibody production [7]. 
Recently, Lindner et al. revealed that IL-21 induces B cells to produce and secrete the active 
form of the cytotoxic serine protease granzyme B (GrB) and gain immune regulatory 
properties by limiting T cell proliferation by a GrB-dependent degradation of T cell receptor 
ζ-chain [8]. In systemic lupus erythematosus, CD19+CD5+ B cells were reported to be one of 
the main sources of GrB [9]. These observations raise the possibility that beside the key role 
of TFH cells in B cell activation, the interaction of IL-21-producing invariant NKT (iNKT) 
cells with B cells and GrB production may also play a potential role in the pathogenesis of 
pSS.  
In our study, we investigated the expression of IL-21 receptor (IL-21R) and GrB of B cell 
subsets, we assessed the IL-21 expression of iNKT cells, and determined the distribution of 
transitional, mature and primarily memory B cell subsets in the peripheral blood of pSS 
patients. 
 
 
Materials and Methods 
 
Patients and healthy individuals 
We enrolled 32Thirty-two pSS patients in the study, who visited our outpatient clinic for 
systemic autoimmune diseases in the Division of Clinical Immunology of the University of 
Debrecen for a regular medical check-up between April and June 2014. Exclusion criteria 
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included other autoimmune, allergic and malignant diseases, pregnancy, immunosuppressive 
or immunomodulating medications and ongoing infections.pSS patients were enrolled in the 
study, recruited from the outpatient clinic for systemic autoimmune diseases at the Division of 
Clinical Immunology, Institute of Medicine, Medical and Health Science Center, University 
of Debrecen, where they received regular follow-up treatment. The diagnosis was based on 
the European-American consensus criteria [10]. Twenty-four age- and sex-matched healthy 
individuals served as controls. 
Among pSS patients, 18 suffered from extraglandular manifestations (EGMs), while 14 had 
glandular symptoms only. The distribution of EGMs of pSS patients were as follows: 
polyarthralgia/polyarthritis n=16, Raynaud’s phenomenon n=7, polyneuropathiesa n=4, 
vasculitis n=3. Vasculitis or other EGMs needing immunosuppressive treatment were newly 
recognised or in inactive status. No patients, or controls enrolled in this study took any 
immunosuppressive or immunomodulating medications, or had ongoing infections during the 
study. Informed written consent was obtained from the subjects, and the study has been 
approved by the Ethics Committee of the University of Debrecen. All experiments carried out 
were in compliance with the Declaration of Helsinki. Data on subjects enrolled in the study 
are summarized in Table 1. 
 
Analysis of GrB production and IL-21R expression of CD19
+
CD5
+
 and CD19
+
CD5
- 
B cells 
For the evaluation of intracellular GrB production of CD19
+
CD5
+
 and CD19
+
CD5
-
 B cell, 
peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood 
sample by Ficoll-Histopaque (Sigma-Aldrich, St Louis, MO, USA) density-gradient 
centrifugation. Cells were then harvested and washed twice and cultured in modified RPMI 
1640 medium with GLUTAMAX
TM
-I (Life Technologies Corporation, Carlsbad, CA, USA) 
supplemented with 100 U/ml penicillin, 100 ng/ml streptomycin and 10% heat-inactivated 
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fetal calf serum ( FCS) (Life Technologies). Cells were stimulated using 6,5 g/ml anti-
human B cell receptor (BCR) antibody (Jackson ImmunoResearch, West Grove, PA, USA) 
and 50 ng/ml recombinant human IL-21 (R&D Systems, Inc., Minneapolis, MN, USA) for 18 
hours at 37°C in an atmosphere containing 5% CO2, based on the protocol described 
previously by Hagn et al. [9]. The transport of de novo synthesized cytokines from the Golgi 
apparatus was inhibited by 10 g/ml brefeldin-A (Sigma-Aldrich). Unstimulated cells served 
as controls. Next, cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-
CD5 and phycoerythrin-cyanine (PC)5-labelled anti-CD19 antibodies (BD Biosciences, San 
Diego, CA, USA and Beckman Coulter Inc, Miami, FL, USA) for 30 min at 4°C. The cells 
then fixed and permeabilized with Intraprep
 
permeabilization reagent (Beckman Coulter) 
according to the manufacturer's instructions, and intracellular GrB were stained with 
phycoerythrin (PE)-conjugated anti-GrB antibody (BD Biosciences).  
For the evaluation of IL-21R expression, anti-CD5-FITC, anti-CD19-PC5 and anti-IL-21R 
(CD360)-PE antibodies were used (BD Biosciences, Beckman Coulter and BioLegend, San 
Diego, CA, USA), and mean fluorescence intensity (MFI) was determined. Mouse 
immunoglobulin (Ig)G1 antibodies were used as isotype control throughout the experiments. 
The measurements were performed on a FACS Calibur flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA). CD19
+
, CD19
+
CD5
+
 and CD19
+
CD5
-
 B cells were quantified as 
their percentage in the entire lymphocyte population. GrB positivity and IL-21R expression 
levels were quantified within the investigated B cell subpopulations. 
 
Assessment of peripheral iNKT cell percentages and their IL-21 expression 
In order to determine iNKT cells from heparinized blood samples, the following monoclonal 
antibodies to cell surface markers were used: FITC-conjugated anti-CD3 and PE-conjugated 
6B11 (BD Biosciences). Samples were processed according to the Coulter Q-PREP protocol 
Formázott: angol (Egyesült Királyság)
Formázott: angol (Egyesült Királyság)
Formázott: angol (Egyesült Királyság)
Formázott: angol (Egyesült Királyság)
7 
 
and system (Beckman Coulter Inc.). Briefly, cells from 50 l of whole blood were stained 
with 10 l of each monoclonal antibody. After 20 min incubation, red blood cells were 
haemolysed and leucocytes were washed in phosphate-buffered saline (PBS) supplemented 
with bovine serum albumin (BSA) (10 mg/l) and sodium-azide (2 mg/l). The cells were fixed 
subsequently using 500 l of 1% paraformaldehyde. 
The cytoplasmic IL-21 content of circulating iNKT cells was also determined by flow 
cytometry. Briefly, isolated PBMCs were cultured in modified RPMI 1640 medium with 
GLUTAMAX
TM
-I (Life Technologies) supplemented with 100 U/ml penicillin, 100 ng/ml 
streptomycin and 10% heat-inactivated fetal calf serum (Life Technologies). Cells were 
stimulated using 25 ng/ml phorbol–myristate–acetate (Sigma Aldrich) and 1 g/ml ionomycin 
(Sigma Aldrich) for 6 hours at 37°C in an atmosphere containing 5% CO2. The transport of de 
novo synthesized cytokines from the Golgi apparatus was inhibited by 10 g/ml brefeldin-A 
(Sigma Aldrich). After stimulation, cells were stained with anti-CD3-FITC and 6B11-PE 
antibodies (BD Biosciences) for 30 min at 4°C. The cells then fixed and permeabilized with 
Intraprep
 
permeabilization reagent (Beckman Coulter Inc) according to the manufacturer's 
instructions, and intracellular cytokines were stained with allophycocyanin (APC)-conjugated 
anti-IL-21 antibody (Biolegend). Mouse IgG1 antibodies were used as isotype control 
throughout the experiments. The measurements were performed on a FACSCalibur flow 
cytometer (Becton Dickinson). The CD3
+
6B11
+
 iNKT cells were quantified as their 
percentage in the entire lymphocyte population, while IL-21
+
 iNKT cell were determined as 
their proportions in the population of CD3
+
6B11
+ 
iNKT cells. 
 
Determination of transitional, mature and primarily memory B cells 
PBMCs were isolated from heparinized venous blood sample by Ficoll-Histopaque (Sigma-
Aldrich) density-gradient centrifugation. Cells were then harvested and washed twice and 
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stained for 20 min at 4°C using specific antibodies. To identify transitional, mature, and 
primarily memory B cell subpopulations, cells were stained with the combination of 
following monoclonal antibodies: PC5-labelled anti-CD19 (Beckman Coulter), Alexa Fluor 
488-labelled anti-CD24 (Biolegend) and PC7-labelled anti-CD38 (BD Biosciences). After 30 
min incubation, leucocytes were washed in phosphate-buffered saline (PBS) supplemented 
with bovine serum albumin (BSA) (10 g/l) and sodium-azide (2 mg/l). The cells were fixed 
subsequently using 500 l of 1% paraformaldehyde. Mouse immunoglobulin (Ig)G1 
antibodies were used as isotype control throughout the experiments. Samples were processed 
according to the Coulter Q-PREP protocol and system (Beckman Coulter Inc., Miami, FL, 
USA). Measurements were performed on a Coulter FC500 flow cytometer (Beckman Coulter 
Inc.). CD19
+
CD24
high
CD38
high
 (transitional), CD19
+
CD24
int
CD38
int
 (mature) and 
CD19
+
CD24
high
CD38
-
 (primarily memory) B cells were quantified as their percentage in the 
CD19
+
 lymphocyte population. 
 
Assessment of anti-dsDNA, anti-Ro/SSA and anti-La/SSB autoantibodies 
As part of the routine diagnostic evaluation, aAutoantibodies were determined in the Regional 
Immunology Laboratory of our Division of Clinical Immunology by enzyme-linked 
immunosorbent assay (ELISA) technique with AUTOSTAT II kits (Hycor Biomedical, 
Indianapolis, IN, USA), according to the manufacturer’s instructions. 
 
Statistical analysis 
The SPSS ver. 20.0 (SPSS Inc., Chicago, IL, UDA) was used for statistical analysis. To assess 
the distribution of the data Kolmogorov-Smirnov test was used. In cases of normal 
distribution, we determined mean ± standard deviation (SD) values and used two-sample t test 
for statistical evaluation of the experimental data. In cases of distributions different from that 
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of normal, median (minimum and maximum) values were calculated, and Mann-Whitney test 
was used. When the strength of the linear relationship between two variables was evaluated, 
Pearson's correlation coefficient was used, while in cases of non-normal distribution, 
Spearman’s correlation coefficient was applied. Differences were considered statistically 
significant at p<0.05. 
 
Results 
 
Granzyme B production capability of B cells is increased in pSS 
We found no significant differences in peripheral blood CD19
+
, CD19
+
CD5
+
 and CD19
+
CD5
-
 
B cell percentages between pSS patients, the subgroups of patients  and healthy controls (data 
not shown). When GrB expressions of these B cell subsets were investigated, in the whole 
CD19
+
 B cell population, significantly enhanced GrB expression was observed in the whole 
group of pSS patients (median (min-max): 5.225 (0.41-28.1)% vs. 3.69 (0.04-7.29)%, 
respectively, p=0.0121), as well as in all subgroups of patients (pSS glandular: median (min-
max): 5.505 (0.41-28.1)% vs. 3.69 (0.04-7.29)%, respectively, p=0.0261; pSS EGMs: median 
(min-max): 4.735 (0.73-22.34)% vs. 3.69 (0.04-7.29)%, respectively, p=0.0486), compared to 
the values measured in the healthy controls (Figure 1).  
When we divided CD19
+
 B cell population on the basis of their CD5 positivity, we found that 
only CD19
+
CD5
+
 B cells expressed GrB significantly higher in each group of pSS patients, 
compared to control values (pSS: median (min-max): 4.59 (1.04-26.45)% vs. 2.8 (0.18-
6.13)%, respectively, p=0.0086; pSS glandular: median (min-max): 6.81 (1.6-26.45)% vs. 2.8 
(0.18-6.13)%, respectively, p=0.0101; pSS EGMs: median (min-max): 4.03 (1.04-23.91)% vs. 
2.8 (0.18-6.13)%, respectively, p=0.0354). (Figure 1) 
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IL-21 receptor expression is enhanced on CD19
+
CD5
+ 
B cells in pSS 
We observed significantly enhanced IL-21R expression on CD19
+
 B cells in the whole group 
of pSS patients (mean ± SD: 3.434 ± 0.929 MFI vs. 2.961 ± 0.585 MFI, respectively, 
p=0.0288), as well as in subgroup of patients with EGMs, compared to values measured in 
healthy individuals (mean ± SD: 3.578 ± 0.901 MFI vs. 2.961 ± 0.585 MFI, respectively, 
p=0.0195) (Figure 2).  
When we divided CD19
+
 B cell population on the basis of their CD5 positivity, we found that 
only CD19
+
CD5
+
 B cells expressed IL-21R significantly higher in the whole group of pSS 
patients (mean ± SD: 3.677 ± 0.894 MFI vs. 3.145 ± 0.564 MFI, respectively, p=0.0114) and 
in the subgroup of patients with EGMs, compared to control values (mean ± SD: 3.834 ± 
0.872 MFI vs. 3.145 ± 0.564 MFI, respectively, p=0.0078) (Figure 2). 
Moreover, we found positive correlation between the percentages of GrB positivity and the 
level of IL-21R expression within both CD19
+
 B cells (R=0.6261, p=0.0001) and CD19
+
CD5
+
 
B cells (R=0.5949, p=0.0003) in pSS (Figure 3A and B). 
 
Elevated intracellular IL-21 cytokine expression of iNKT cells in pSS patients 
We observed no significant differences in the peripheral blood iNKT percentages between 
pSS patients and controls (data not shown). However, in the pSS patient population, we found 
significantly elevated percentages of IL-21-producing iNKT cells within iNKT population, 
compared to the values determined in healthy individuals (median (min-max): 2.81 (0.1-
29.02)% vs. 1.16 (0.1-12.1)%, respectively, p=0.0141). 
 
Transitional, mature and primarily memory B cell proportions and presence of 
autoantibodies in pSS 
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The distribution of B cells was also evaluated in the study (Figure 4). The percentages of 
CD19
+
CD24
high
CD38
high
 transitional B cells were significantly higher in pSS patients 
compared to healthy control (median (min-max): 5.21 (1.68-27.83)% vs. 3.19 (0.57-13.4)%, 
respectively, p=0.0079). Regarding the subgroups of patients, subjects suffering from EGMs 
had also elevated percentages (median (min-max): 5.44 (3.41-27.83)% vs. 3.19 (0.57-13.4)%, 
respectively, p=0.0038), while values of patients with glandular symptoms did not differ 
significantly from the results of healthy individuals.  
The proportions of CD19
+
CD24
int
CD38
int
 mature B cells were significantly elevated in the 
whole group of pSS patients (mean ± SD: 52.241 ± 15.245% vs. 39.628 ± 13.958%, 
respectively, p=0.0021), as well as in both of pSS subgroups (pSS glandular: mean ± SD: 
50.885 ± 17.618% vs. 39.628 ± 13.958%, respectively, p=0.0343; pSS EGMs: mean ± SD: 
53.296 ± 13.555% vs. 39.628 ± 13.958%, respectively, p=0.0026), compared to control 
values.  
On the contrary, the frequency of CD19
+
CD24
high
CD38
-
 primarily memory B cells were 
significantly decreased in all groups of pSS patients, compared to controls (pSS: mean ± SD: 
24.166 ± 13.712% vs. 35.083 ± 13.887%, respectively, p=0.0046; pSS gland: mean ± SD: 
23.798 ± 14.422% vs. 35.083 ± 13.887%, respectively, p=0.0214; pSS EGMs: mean ± SD: 
24.452 ± 13.551% vs. 35.083 ± 13.887%, respectively, p=0.0165). 
Additionally, we found a positive correlation between the percentages of GrB positive CD19
+
 
B cells and mature B cells (R=0.4022, p=0.0224), while a negative correlation between the 
percentages of GrB positive CD19
+
 B cells and primarily memory B cells (R=-0.4565, 
p=0.0086) (Figure 5A and B). Similarly, positive correlation was observed between the level 
of IL-21R expression of CD19
+
 B cells (R=0.4935, p=0.0041), while negative correlation was 
revealed between the level of IL-21R expression of CD19
+
 B cells and primarily memory B 
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cells (R=-0.4696, p=0.0067) (Figure 5C and D). We observed no further correlations between 
the other investigated parameters. 
Thirteen individuals were positive for anti-Ro/SSA and/or anti-La/SSB antibody among pSS 
patients. We observed no association between the presence of autoantibodies and the 
investigated parameters. 
 
 
 
 
Discussion 
 
Formerly, we reported higher level of circulating IL-21 in pSS and found increased 
circulating TFH cell percentages in the disease [6]. In the present study, we observed elevated 
IL-21 expression of iNKT cells, which, along with the increased IL-21R expression of B 
cells, may contribute to the enhanced B cell activation in pSS. Interestingly, B cells 
expressing enhanced IL-21R on surface were typically positive for surface antigen CD5. 
Furthermore, when we divided patients into two groups based on the presence or absence of 
EGMs, significant increase in expression of IL-21R was found only in the group of EGM 
patients, compared to the control values. This observation is in line with our previous results, 
namely significantly elevated ratio of peripheral TFH cells were observed only in pSS patients 
with EGMs and not in those without EGMs; furthermore, higher IL-21 cytokine 
concentrations were associated with the presence of EGMs [6]. Regarding the IL-21 over-
production of iNKT cells, we did not find marked difference between the subgroups of 
patients. 
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Basically, IL-21 stimulation on B cells may have at least three outcomes. In the absence of 
both B cell receptor (BCR) engagement and T cell help, it induces B cell apoptosis [11]. In 
the presence of CD40 ligation and either a BCR or a Toll-like receptor signal, IL-21 
stimulation fundamentally promotes B cell activation and differentiation processes into 
memory and plasma cells. However, the combination of IL-21 stimulation and BCR 
engagement in the absence of CD40 ligation enables B cells to produce and secrete the active 
form of GrB [12] (Figure 6). Beside its important and well-known function in antiviral 
immune responses, GrB secretion plays a potential role in the regulation of autoimmune 
responses as well, through different mechanisms. The spectrum of functions exhibited by GrB 
includes antigen processing, matrix degradation, cleavage and activation of inflammatory 
cytokines and immunoregulatory effects [13,14]. Consequently, GrB-producing B cells may 
acquire a regulatory function and effects on other immune cells; furthermore, leakage of GrB 
in the cytoplasm may also result in the apoptotic demise of autoreactive B cells [15]. Based 
on our observations, GrB expression of B cells, especially in CD19
+
CD5
+
 ones, is 
significantly increased in pSS regardless to the presence of EGMs. Importantly, we observed 
a clear positive correlation between GrB production and IL21R expression on CD19
+
 B and 
CD19
+
CD5
+
 B cells, as well. Additionally, we also found further associations with the altered 
distribution of transitional, mature and primarily memory B cells. Our observations, namely 
proportions of mature B cells are elevated, while percentages of primarily memory B cells are 
decreased in pSS, are in line with former observations [16] pointing on the hyperactivated 
state of B cells in pSS patients. In our study, we revealed that not only IL21R expression but 
also GrB production on CD19
+
 B cells correlate positively with the frequency of 
CD19
+
CD24
high
CD38
high
 transitional and CD19
+
CD24
int
CD38
int
 mature B cell subsets, and 
correlate negatively with CD19
+
CD24
high
CD38
-
 primarily memory B cells. 
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Conclusions 
 
Based on our results, we assume, that parallel with the pathologic B cell activation and 
enhanced autoantibody production driven by the expansion of TFH cells and their pronounced 
IL-21 expression, GrB production is mainly induced in CD5
+
 B cell subsets in pSS, which 
could be part of an increased counter-regulatory reaction, presumably compensating the 
derailed, disproportional immune responses. We believe that further investigation on the 
activation and function of GrB-producing regulatory B cells will open new avenues to 
understand the B cell operation and autoimmune processes in pSS; furthermore, the 
modulation of these cells could be a potentially powerful element of the novel therapeutic 
selection in the disease. 
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Tables 
 
 
 
Table 1. The demographic characteristics of subjects enrolled in the study. 
(EGMs: extraglandular manifestations, pSS: primary Sjögren’s syndrome)
 Healthy 
individuals 
pSS Patients Patients with 
EGMs 
Patients without 
EGMs 
Number 24 32 18 14 
Age (years), mean ± SD 53.69 ± 9.12 58.98 ± 7.67 60.48 ± 6.47 57.04 ± 9.12 
Sex (man/woman) 2/22 2/30 1/17 1/13 
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Figure legends 
 
Figure 1. Granzyme B expression of B cell subsets. Box plots show median, upper and 
lower quartiles, lines extending vertically from boxes indicate 5-95 percentile ranges. 
Statistically significant differences are indicated by (*). 
 
Figure 2. Interleukin-21 receptor expression of B cell subsets. Box plots show median, 
upper and lower quartiles, lines extending vertically from boxes indicate 5-95 percentile 
ranges. Statistically significant differences are indicated by (*).  
 
Figure 3. Correlation analysis between granzyme B and interleukin-21 receptor 
expression in (A) CD19
+
 B cells (R=0.6261, p=0.0001) and (B) CD19
+
CD5
+
 B cells 
(R=0.5949, p=0.0003). 
 
Figure 4. Percentages of transitional, mature and primarily memory B cells. Box plots 
show median, upper and lower quartiles, lines extending vertically from boxes indicate 5-95 
percentile ranges. Statistically significant differences are indicated by (*).  
 
Figure 5. Correlation analysis between granzyme B and interleukin-21 receptor 
expression and B cell subsets. Associations between granzyme B expression of CD19
+
 B 
cells and (A) percentages of CD19
+
CD24
int
CD38
int
 mature B cells (R=0.4022, p=0.0224) as 
well as (B) percentages of CD19
+
CD24
high
CD38
- 
primarily memory B cells (R=-0.4565, 
p=0.0086). Correlations between interleukin-21 receptor expression of CD19
+
 B cells and (C) 
percentages of CD19
+
CD24
int
CD38
int
 mature B cells (R=0.4935, p=0.0041) as well as (D) 
percentages of CD19
+
CD24
high
CD38
- 
primarily memory B cells (R=-0.4696, p=0.0067). 
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Figure 6. Possible results of interlukin-21 (IL-21) stimulation on B cells. In the presence 
of CD40 ligation and either a B cell receptor (BCR) or a Toll-like receptor signal, IL-21 
stimulation fundamentally promotes B cell activation and differentiation into memory and 
plasma cells [6]. The combination of IL-21 stimulation and BCR engagement in the absence 
of CD40 ligation enables B cells to produce and secrete active form of granzyme B (GrB). 
GrB-producing B cells may acquire antiviral immune function and/or a regulatory function on 
themselves or other immune cells including T and NKT cells [15]. In the absence of both 
(BCR) engagement and T cell help, IL-21 stimulation induces B cell apoptosis [11].  
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